CONCISE REPORT

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

Christopher P Denton,1 Thomas Krieg,2 Loic Guillemin,3 Barbara Schwierin,4 Daniel Rosenberg,4 Mariabeth Silkey,4 Maurice Zultak,4 Marco Matucci-Cerinic,5 on behalf of the DUO Registry investigators*

ABSTRACT

Objectives The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc).

Methods The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers.

Results Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.6% for anticentromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group.

Conclusions This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies.

Systemic sclerosis (SSc) is a multisystem autoimmune disease characterised by microvascular damage and excessive fibrosis of the skin and various internal organs. Limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) subsets are also associated with the presence of a number of autoantibodies, the expression of which can be useful in the diagnosis, prognosis and SSc disease management.1

The European Medicines Agency (EMA) requested the establishment of a prospective registry of patients with ongoing digital ulcers associated with SSc as a licensing requirement for bosentan in this indication. The Digital Ulcers Outcome (DUO) Registry enrolls patients with digital ulcer disease regardless of their treatment status; however, a large proportion are receiving bosentan. This study provides valuable insights into this patient group and here we describe the clinical and autoantibody characteristics of these patients at enrolment.

METHODS

The DUO Registry was initiated in April 2008 as an EMA postapproval commitment (after approval of a new indication for bosentan ‘to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease’).2 Participating centres received approval from relevant national and local ethics committees, data protection and health authorities. In line with an observational study design, physicians were asked to enter all consenting consecutive patients with ongoing digital ulcers associated with SSc, irrespective of treatment regimen. Patients received standard medical care and follow-up as determined by their physician. Data definitions were informed by literature3 and scientific committee consensus. Data collection included demographics, SSc disease duration, underlying disease classification (lcSSc, dcSSc, overlap SSc/mixed connective tissue disease and other), internal organ manifestations, autoantibodies, history of interventions/complications related to digital ulcers, ongoing complications related to digital ulcers, and ongoing medications and functional assessment based on a disease-specific questionnaire. The presence of antinuclear antibodies, anti-scleroderma-70 antibodies, anticientromere antibodies (ACA), anti-RNA polymerase 3, anti-U1 ribonucleoprotein and anti-U3 ribonucleoprotein were recorded. All serology tests and other data collection parameters were collected if performed. Quality assurance comprised automatic online quality checks and annual source data verification on 10% of the patients.

Data analysis

Enrolment data for the antibody subsets were analysed cross-sectionally for differences by group. SAS statistical software was used for analysing the data. Descriptive statistics (mean, median, SD, 95% CI, minimum, maximum) are provided for numerical variables. Categorical variables are summarised by counts and percentages and 95% CI.

RESULTS

As of 19 November 2010, a total of 2439 patients had been enrolled into the DUO Registry from 271
participants in 18 European countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland and UK).

Study cohort characteristics

The mean age of the patients enrolled was 54.6 years (SD 14.1) and the majority were women. Age at first Raynaud’s phenomenon was on average 39.8 years and age at first digital ulcer was 46.7 years. At the time of enrolment, 60.0% (1426/2377) had at least one digital ulcer (data were missing for 62 patients). All patients who had no current digital ulcers at enrolment had a history of digital ulcer disease. Overall, 52.2% of the patients were classified as lcSSc, 36.9% as dcSSc, 6.8% as overlap SSC/SSS mixed connective tissue disease, and 4.1% had other diseases (eg, systemic lupus erythematosus, dermatomyositis, vasculitis or SSC not further specified) (data were missing for 44 patients).

At enrolment, gastrointestinal tract manifestations had occurred in more than half of the patients (55.7%). Also common were lung fibrosis (41.3%), pulmonary arterial hypertension (PAH) (15.0%) and heart manifestations (10.7%). Almost half of all patients (47.4%) were receiving treatment with bosentan or another ERA (endothelin receptor antagonist), with a similar proportion receiving calcium antagonists and approximately one third receiving prostanoids (see supplementary table S1, available online only).

Antibody distribution

Almost all, 95.7%, (2055/2179) of patients tested were positive for antinuclear antibodies, 45.2% (854/1888) for anti-scleroderma-70 antibodies, 45.6% (775/1778) for ACA, 9.9% (86/867) for anti-RNA polymerase 3, 9.7% (120/1243) for anti-U1 ribonucleoprotein and 4.9% (39/799) for anti-U3 ribonucleoprotein. Few patients had a combination of antibodies. The combination with the highest occurrence was anti-sclerodema-70 plus ACA, 2.3% (56/2439), followed by anti-scleroderma-70 plus anti-U1 ribonucleoprotein, 1.8% (43/2439), anti-scleroderma-70 plus anti-RNA polymerase 3, 1.5% (36/2439), ACA plus anti-U1 ribonucleoprotein, 1.4% (34/2439), ACA plus anti-RNA polymerase 3, 1.4% (34/2439) and anti-U1 ribonucleoprotein plus anti-U3 ribonucleoprotein, 1.3% (31/2439).

SSc disease characteristics by antibody status

Patients positive for ACA were predominantly classified as lcSSc (82.9%; table 1). From the patients positive for anti-scleroderma-70 antibodies, a high proportion were classified as dcSSc (66.6%) and a lower proportion were classified as lcSSc (29.4%). Lung fibrosis was most frequent in the anti-scleroderma-70 subset (62.2%) compared with other antibody subsets (22.3–41.9%). Gastrointestinal manifestations showed a similar high proportion in all antibody subgroups, except for patients who were anti-U3 ribonucleoprotein positive. The frequencies of PAH and kidney manifestations were generally similar across the antibody subsets, although the proportion among patients with anti-U3 ribonucleoprotein was slightly higher; heart manifestations were highest in patients with anti-scleroderma-70 and anti-U1 ribonucleoprotein and lowest in patients with ACA (table 2). The proportion of patients with previous digital ulcer complications and interventions was broadly similar in the anti-scleroderma-70 subgroup and the ACA subgroup; the most marked exception was for surgical amputation, which occurred almost twice as frequently in patients with ACA (14.6%) compared with anti-scleroderma-70-positive patients (7.9%) (table 3).
<table>
<thead>
<tr>
<th>Manifestation</th>
<th>Anti-Scl-70 (N=854)</th>
<th>Anti-RNA Pol 3 (N=86)</th>
<th>Anti-U1 RNP (N=120)</th>
<th>Anti-U3 RNP (N=39)</th>
<th>ACA (N=775)</th>
<th>Anti-U1 RNP (N=120)</th>
<th>Anti-U3 RNP (N=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung fibrosis, n/N (%) (95% CI)</td>
<td>873/2085 (41.9)</td>
<td>531/854 (62.2)</td>
<td>43/854 (5.0)</td>
<td>220/2085 (10.6)</td>
<td>173/775 (22.3)</td>
<td>63/120 (52.5)</td>
<td>5/39 (12.8)</td>
</tr>
<tr>
<td>PAH, n/N (%) (95% CI)</td>
<td>307/2085 (14.7)</td>
<td>133/854 (15.6)</td>
<td>12/86 (14.0)</td>
<td>120/775 (15.5)</td>
<td>26/775 (3.4)</td>
<td>10/120 (8.3)</td>
<td>5/39 (12.8)</td>
</tr>
<tr>
<td>Kidney manifestations, n/N (%) (95% CI)</td>
<td>105/2085 (5.0)</td>
<td>43/854 (5.0)</td>
<td>7/86 (8.1)</td>
<td>51/86 (59.3)</td>
<td>440/775 (56.8)</td>
<td>15/39 (38.5)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal manifestations, n/N (%) (95% CI)</td>
<td>1182/2085 (57.2)</td>
<td>488/854 (56.4)</td>
<td>51/86 (59.3)</td>
<td>410/775 (53.2)</td>
<td>63/120 (52.5)</td>
<td>5/39 (12.8)</td>
<td></td>
</tr>
<tr>
<td>Heart manifestations, n/N (%) (95% CI)</td>
<td>220/2085 (10.6)</td>
<td>105/854 (12.3)</td>
<td>6/86 (7.0)</td>
<td>47/775 (6.1)</td>
<td>63/120 (52.5)</td>
<td>5/39 (12.8)</td>
<td></td>
</tr>
</tbody>
</table>

The denominator N varies according to the number of available observations.

*Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups.

The proportion of anti-U1 ribonucleoprotein antibodies varies significantly between different countries and may be influenced by various factors, such as the prevalence of different autoantibodies. Comparisons between different studies should therefore be interpreted with caution.

There are a number of limitations in this study, in particular the absence of specific antibody testing, which limits the ability to draw conclusions about the role of specific autoantibodies.

In conclusion, this study provides important insights into the role of specific autoantibodies in the development of disease manifestations in SSc patients. Further research is needed to better understand the mechanisms underlying these associations.

**DISCUSSION**

The findings of the DUO Registry regarding the burden of disease manifestations in SSc patients with digital ulcers may have important implications for clinical practice. These findings highlight the importance of early and aggressive intervention in the management of digital ulcers to prevent the development of more severe complications.

**Acknowledgments**

This study was supported by grants from the European League Against Rheumatism (ELAR) and the German Research Foundation (DFG).

**Compliance with ethical standards**

The authors declare that they have no conflict of interest.
was initiated following EMA approval of bosentan, and it is possible that patient entry into the registry was biased towards patients receiving bosentan. Therefore, there are limitations in the application of these data to the wider SSC population. Nevertheless, this study provides, and will continue to provide, valuable prospectively collected data from a large cohort of over 2000 SSC patients. The strengths include the prospective nature of data collection and the strong framework of research governance compared with that of previous studies. The multinational and multicentre nature of this registry offers the potential for comparison of different patient populations and healthcare systems.

**CONCLUSION**

This report provides the first analysis of data from the large, multinational DUO Registry confirming the high clinical burden of digital ulcers in patients with SSC across antibody subsets, with early occurrence and high frequency in patients with dcSSc. The feasibility and utility of the DUO Registry is confirmed by the findings of this study.

**Contributors**

Registry design: CPD, TK, LG, BS, DR, MS, MZ, MMAC; data acquisition: CPD, TK, LG, BR, DR, MS, MZ, MMAC; statistical analysis: MS, DR. All authors were involved in the drafting and reviewing of the manuscript and approved the final version.

**Acknowledgements**

The authors gratefully acknowledge all investigators involved in this registry. The authors would like to thank Lisa Thomas, Elements Communications Ltd, for providing editorial assistance, funded by Actelion Pharmaceuticals Ltd.

**Funding**

This registry was sponsored by Actelion Pharmaceuticals Ltd. The registry sponsor was involved in the registry design, and in the collection, analysis and interpretation of data.

**Competing interests**

BS, DR, MS and MZ are employees of Actelion Pharmaceuticals Ltd, the manufacturers of bosentan. The non-Actelion authors who are authors of this manuscript have received consultancy fees or research grant funding from Actelion Pharmaceuticals Ltd.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Correction notice**

This article has been corrected since it was published Online First. The author list has been amended.

**REFERENCES**